OncoMatch/Clinical Trials/NCT04752137
Intraoperative Tumor Margin Identification With ICG Dye Imaging
Is NCT04752137 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Indocyanine green and SPY-PHI for benign neoplasm.
Treatment: Indocyanine green · SPY-PHI — In this research study we want to learn more about the use of indocyanine green (ICG) during bone or soft tissue mass resections. Indocyanine green (ICG) is a type of dye that is used in medical diagnostics. We want to determine if ICG-guided tumor resection is more effective in obtaining negative margins. Lastly, we want to assess traditional oncologic outcomes of local recurrence, time to metastatic disease, and overall and disease specific survival.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Lab requirements
Kidney function
Patients in renal failure who are not cleared for ICG administration by their primary physician or oncologist [excluded]
Patients in renal failure who are not cleared for ICG administration by their primary physician or oncologist [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify